Psychopathological Symptoms in Patients with Primary Hyperaldosteronism – Possible Pathways

Abstract

A close comorbidity between endocrine diseases and psychopathological symptoms has been described in the literature. Until now only a few studies have reported about an increased anxiety and depressive symptoms in patients with primary hyperaldosteronism (PHA). The exact pathways of psychiatric comorbidities have not been totally clarified yet, although the renin-angiotensin-aldosterone-system has gained more attention in research on anxiety and depression. There are several structures and factors, which could mediate anxiety or a depressive symptomatology. Additionally a possible influence of the standardised treatment with a mineralocorticoidreceptor (MR) antagonist or adrenalectomy should be investigated as they have been shown to affect mood. Psychiatric comorbidities are not only an additional burden in these patients, but as depression and anxiety are additional risk factors in patients with cardiovascular diseases. Possible pathomechanisms in the relation between PHA and psychiatric symptoms should be more closely investigated. For the clinical practice a regular screening for psychiatric comorbidities and an adequate treatment are required.

Key words

aldosterone - renin - arterial hypertension - Conn’s syndrome - anxiety - depression

• References

• 1 Sonino N, Fallo F, Fava GA. Psychosomatic aspects of Cushing's syndrome. Rev Endocr Metab Disord 2010; 11: 95-104
• 2 Tiemensma J, Biermasz NR, van der Mast RC, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA. Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, In Patients after Long-Term Cure of Acromegaly. J Clin Endocrinol Metab 2010; 95: E392-E402
• 3 Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J, McGregor AM. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502. Q J Med 1991; 81: 891-906
• 4 Bunevicius R, Prange Jr AJ. Thyroid disease and mental disorders: cause and effect or only comorbidity?. Curr Opin Psychiatry 2010; 23: 363-368
• 5 Avery TL. Primary hyperaldosteronism and depression. N Z Med J 1984; 97: 537
• 6 Khurshid KA, Weaver ME. Conn’s syndrome presenting as depression. Am J Psychiatry 2005; 162: 1226
• 7 Malinow KC, Lion JR. Hyperaldosteronism (Conn’s disease) presenting as depression. J Clin Psychiatry 1979; 40: 358-359
• 8 Tritos NA. Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass. Nat Clin Pract Endocrinol Metab 2007; 3: 547-551
• 9 Sonino N, Fallo F, Fava GA. Psychological aspects of primary aldosteronism. Psychother Psychosom 2006; 75: 327-330
• 10 Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, Fava GA, Fallo F. Psychological Assessment of Primary Aldosteronism: A Controlled Study. J Clin Endocrinol Metab 2011; 96: E878-E883
• 11 Apostolopoulou K, Künzel H, Gerum S, Merkle K, Schulz S, Fischer E, Pallauf A, Brand V, Bidlingmaier M, Endres S, Beuschlein F, Reincke M. Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross sectional study. World J Biol Psychiatry: accepted.
• 12 Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 1360-1364
• 13 Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011; 96: 2904-2911
• 14 Lippi G, Montagnana M, Favaloro EJ, Franchini M. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost 2009; 35: 325-336
• 15 Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290: 215-221
• 16 Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
• 17 Strohle A, Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 2003; 36: S207-S214
• 18 Kem DC, Weinberger MH, Gomez-Sanchez C, Kramer NJ, Lerman R, Furuyama S, Nugent CA. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism. J Clin Invest 1973; 52: 2272-2277
• 19 de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005; 6: 463-475
• 20 De Kloet ER, Derijk R. Signaling pathways in brain involved in predisposition and pathogenesis of stress-related disease: genetic and kinetic factors affecting the MR/GR balance. Ann N Y Acad Sci 2004; 1032: 14-34
• 21 Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404
• 22 Yau JL, Hibberd C, Noble J, Seckl JR. The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res Mol Brain Res 2002; 106: 117-123
• 23 Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992; 55: 621-626
• 24 Yau JL, Noble J, Hibberd C, Seckl JR. Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 2001; 306: 161-164
• 25 Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 2008; 54: 90-97
• 26 Hlavacova N, Bakos J, Jezova D. Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J Psychopharmacol 2010; 24: 779-786
• 27 Zhou M, Bakker EH, Velzing EH, Berger S, Oitzl M, Joels M, Krugers HJ. Both mineralocorticoid and glucocorticoid receptors regulate emotional memory in mice. Neurobiol Learn Mem 2010; 94: 530-537
• 28 Ferguson D, Sapolsky R. Overexpression of mineralocorticoid and transdominant glucocorticoid receptor blocks the impairing effects of glucocorticoids on memory. Hippocampus 2008; 18: 1103-1111
• 29 Schulz K, Korz V. Emotional and cognitive information processing: relations to behavioral performance and hippocampal long-term potentiation in vivo during a spatial water maze training in rats. Learn Mem 2010; 17: 552-560
• 30 Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547-573
• 31 Xing GQ, Russell S, Webster MJ, Post RM. Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 2004; 7: 143-153
• 32 Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 2008; 13: 786-799
• 33 Klok MD, Alt SR, Irurzun Lafitte AJ, Turner JD, Lakke EA, Huitinga I, Muller CP, Zitman FG, Ronald de Kloet E, Derijk RH. Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res 2011; 45: 871-878
• 34 Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?. Hypertension 2008; 51: 727-733
• 35 Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 2011; 1-19
• 36 Johnson AK, Grippo AJ. Sadness and broken hearts: neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression. J Physiol Pharmacol 2006; 57 (Suppl. 11) 5-29
• 37 Holsboer F, Gerken A, Stalla GK, Muller OA. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. Am J Psychiatry 1987; 144: 229-231
• 38 Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A. The renin-angiotensin-aldosterone system in patients with depression compared to controls – a sleep endocrine study. BMC Psychiatry 2003; 3: 15
• 39 Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P. Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005; 36: 544-548
• 40 Hallberg L, Westrin A, Isaksson A, Janelid S, Träskman-Bendz L, Brundin L. Decreased aldosterone in the plasma of suicide attempters with major depressive disorder. Psychiatry Res 2011; 187: 135-139
• 41 Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001; 62: 77-91
• 42 Venning EH, Dyrenfurth I, Beck JC. Effect of anxiety upon aldosterone excretion in man. J Clin Endocrinol Metab 1957; 17: 1005-1008
• 43 Hullin RP, Jerram TC, Lee MR, Levell MJ, Tyrer SP. Renin and aldosterone relationships in manic depressive psychosis. Br J Psychiatry 1977; 131: 575-581
• 44 Altamura AC, Gomeni R, Sacchetti E, Smeraldi E. Plasma and intracellular kinetics of lithium after oral administration of various lithium salts. Eur J Clin Pharmacol 1977; 12: 59-63
• 45 Altamura AC, Morganti A. Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate. Psychopharmacologia 1975; 45: 171-175
• 46 Murck H, Uhr M, Ziegenbein M, Kunzel H, Held K, Antonijevic IA, Schussler P, Steiger A. Renin-angiotensin-aldosterone system, HPA-axis and sleep-EEG changes in unmedicated patients with depression after total sleep deprivation. Pharmacopsychiatry 2006; 39: 23-29
• 47 Saavedra JM, Ando H, Armando I, Baiardi G, Bregonzio C, Juorio A, Macova M. Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 2005; 128: 227-238
• 48 Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 2007; 1142: 92-99
• 49 Saavedra JM, Armando I, Bregonzio C, Juorio A, Macova M, Pavel J, Sanchez-Lemus E. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 2006; 31: 1123-1134
• 50 Gard PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 1999; 45: 1030-1034
• 51 Muldoon MF, Waldstein SR, Ryan CM, Jennings JR, Polefrone JM, Shapiro AP, Manuck SB. Effects of six anti-hypertensive medications on cognitive performance. J Hypertens 2002; 20: 1643-1652
• 52 Hishimoto A, Shirakawa O, Nishiguchi N, Hashimoto T, Yanagi M, Nushida H, Ueno Y, Maeda K. Association between a functional polymorphism in the renin-angiotensin system and completed suicide. J Neural Transm 2006; 113: 1915-1920
• 53 Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, Zwanzger P, Haberger C, Zill P, Ising M, Deiml T, Uhr M, Illig T, Wichmann HE, Modell S, Nothdurfter C, Holsboer F, Muller-Myhsok B, Moller HJ, Rupprecht R, Bondy B. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 2006; 11: 1003-1015
• 54 Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H, Ingram MJ. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1113-1118
• 55 Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry 1997; 54: 915-922
• 56 Sneed JR, Culang-Reinlieb ME. The vascular depression hypothesis: an update. Am J Geriatr Psychiatry 2011; 19: 99-103
• 57 Hwang JP, Lee TW, Tsai SJ, Chen TJ, Yang CH, Lirng JF, Tsai CF. Cortical and subcortical abnormalities in late-onset depression with history of suicide attempts investigated with MRI and voxel-based morphometry. J Geriatr Psychiatry Neurol 2010; 23: 171-184
• 58 Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 2010; 42: 435-439
• 59 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
• 60 Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6: 363-368
• 61 Douma BR, Korte SM, Buwalda B, la Fleur SE, Bohus B, Luiten PG. Repeated blockade of mineralocorticoid receptors, but not of glucocorticoid receptors impairs food rewarded spatial learning. Psychoneuroendocrinology 1998; 23: 33-44
• 62 Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, Kellner M. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 2007; 32: 232-238
• 63 Braszko JJ. AT(2) but not AT(1) receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats. Behav Brain Res 2002; 131: 79-86
• 64 Arregui A, Perry EK, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J Neurochem 1982; 38: 1490-1492
• 65 Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology 2004; 62: 363-368
• 66 Kolsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R. ACE I/D polymorphism is a risk factor of Alzheimer’s disease but not of vascular dementia. Neurosci Lett 2005; 377: 37-39
• 67 Born J, DeKloet ER, Wenz H, Kern W, Fehm HL. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol 1991; 260: E183-E188
• 68 Born J, Steinbach D, Dodt C, Fehm HL. Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. J Clin Endocrinol Metab 1997; 82: 1106-1110
• 69 Steiger A, Rupprecht R, Spengler D, Guldner J, Hemmeter U, Rothe B, Damm K, Holsboer F. Functional properties of deoxycorticosterone and spironolactone: molecular characterization and effects on sleep-endocrine activity. J Psychiatr Res 1993; 27: 275-284
• 70 Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, Saponara M, Letizia C. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-172
• 71 Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010; 24: 532-537
• 72 Brandenberger G, Charifi C, Muzet A, Saini J, Simon C, Follenius M. Renin as a biological marker of the NREM-REM sleep cycle: effect of REM sleep suppression. J Sleep Res 1994; 3: 30-35
• 73 Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H423-H433
• 74 Hlavacova N, Jezova D. Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul 2008; 42: 147-153
• 75 Hendler NH. Spironolactone prophylaxis in manic-depressive disease. J Nerv Ment Dis 1978; 166: 517-520
• 76 Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J Psychopharmacol 2009; 23: 985-987
• 77 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214
• 78 Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, Kellner M. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 2010; 44: 339-346
• 79 Holmes MC, Yau JL, French KL, Seckl JR. The effect of adrenalectomy on 5-hydroxytryptamine and corticosteroid receptor subtype messenger RNA expression in rat hippocampus. Neuroscience 1995; 64: 327-337
• 80 Briones-Aranda A, Castillo-Salazar M, Picazo O. Adrenalectomy modifies the hippocampal 5-HT(1A) receptors and the anxiolytic-like effect of 8-OH-DPAT in rats. Pharmacol Biochem Behav 2009; 92: 182-189
• 81 Coe SG, Tan WW, Fox TP. Cushing’s syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med 2008; 23: 875-878
• 82 Mishra AK, Agarwal A, Gupta S, Agarwal G, Verma AK, Mishra SK. Outcome of adrenalectomy for Cushing’s syndrome: experience from a tertiary care center. World J Surg 2007; 31: 1425-1432
• 83 Ding XF, Li HZ, Yan WG, Gao Y, Li XQ. Role of adrenalectomy in recurrent Cushing’s disease. Chin Med J (Engl) 2010; 123: 1658-1662
• 84 Cohen SI. Cushing’s syndrome: a psychiatric study of 29 patients. Br J Psychiatry 1980; 136: 120-124
• 85 Voigt KH, Bossert S, Bretschneider S, Bliestle A, Fehm HL. Disturbed cortisol secretion in man: contrasting Cushing’s disease and endogenous depression. Psychiatry Res 1985; 15: 341-350
• 86 Watkins LL, Blumenthal JA, Davidson JR, Babyak MA, McCants Jr CB, Sketch Jr MH. Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. Psychosom Med 2006; 68: 651-656